LEXINGTON, Mass., Apr 24, 2012 (BUSINESS WIRE) –AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report
unaudited consolidated financial results for the quarter ended March 31,
2012 after the U.S. financial markets close on Tuesday, May 1, 2012. The
announcement will be followed by a conference call and webcast with
slides at 4:30 p.m. ET during which management will discuss the
company’s financial results, commercial progress and development
programs.
To access the conference call via telephone, please dial (877) 412-6083
from the United States or (702) 495-1202 for international access. A
telephone replay will be available from approximately 5:30 p.m. ET on
May 1, 2012 through midnight May 8, 2012. To access a replay of the
conference call, dial (855) 859-2056 from the United States or (404)
537-3406 for international access. The pass code for the live call and
the replay is 73223897.
The call will be webcast with slides and accessible through the
Investors section of the company’s website at www.amagpharma.com.
The webcast replay will be available from approximately 5:30 p.m.
ET on May 1, 2012 through midnight June 1, 2012.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
development and commercialization of a therapeutic iron compound to
treat iron deficiency anemia. AMAG manufactures and sells Feraheme(R)
(ferumoxytol) Injection for intravenous use. For additional company or
product information, please visit www.amagpharma.com
or http://feraheme.com.
Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.
SOURCE: AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303
